Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Glycoprotein Metabolic Disorders: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Glycoprotein Metabolic Disorders: 1 US clinical trial tracked, none currently recruiting.

Glycoprotein Metabolic Disorders is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Masonic Cancer Center, University of Minnesota, running 1 of these trials.

Enrollment posture brief

Registry condition glycoprotein-metabolic-disorders

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Glycoprotein Metabolic D (th…0%
Open-enrollment share among volume-matched conditions near Glycoprotein Metabolic Disorders

Glycoprotein Metabolic Disorders has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Glycoprotein Metabolic Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Glycoprotein Metabolic Disorders is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Glycoprotein Metabolic Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

cALD SR-A (Standard-Risk, Regimen A) Drug
1 trials
Osteopetrosis Haploidentical Only Preparative Regimen Drug
1 trials
Osteopetrosis Only Preparative Regimen Drug
1 trials
IMD Preparative Regimen Drug
1 trials
Stem Cell Transplantation Biological
1 trials

US sites by state

Facility locations filed on Glycoprotein Metabolic Disorders trials. A trial with sites in several states counts in each.

Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Glycoprotein Metabolic Disorders page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glycoprotein Metabolic Disorders condition card totals 1 registered trials; most-linked intervention cALD SR-A (Standard-Risk, Regimen A); top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.